222 related articles for article (PubMed ID: 19462433)
21. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
22. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab-induced scalp psoriasis with severe alopecia.
Özkur E; Altunay İK; Leblebici C; Topkarcı Z; Erdem Y
Dermatol Ther; 2019 Sep; 32(5):e13033. PubMed ID: 31350777
[TBL] [Abstract][Full Text] [Related]
24. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.
Darrigade AS; Milpied B; Truchetet ME; Schaeverbeke T; Laharie D; Zerbib F; Beylot-Barry M; Jouary T; Taïeb A; Ezzedine K; Seneschal J
Acta Derm Venereol; 2017 Jun; 97(6):731-734. PubMed ID: 28218339
[TBL] [Abstract][Full Text] [Related]
25. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
Broge T; Nguyen N; Sacks A; Davis M
Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
[No Abstract] [Full Text] [Related]
26. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics.
Stoffel E; Maier H; Riedl E; Brüggen MC; Reininger B; Schaschinger M; Bangert C; Guenova E; Stingl G; Brunner PM
Br J Dermatol; 2018 May; 178(5):1151-1162. PubMed ID: 29143979
[TBL] [Abstract][Full Text] [Related]
27. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
[TBL] [Abstract][Full Text] [Related]
28. [Patient information. Biological agents in inflammatory bowel disease].
Van Domselaar M
Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
[No Abstract] [Full Text] [Related]
29. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
30. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
[TBL] [Abstract][Full Text] [Related]
31. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
32. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
34. Treatment of psoriasis with adalimumab.
Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab-induced psoriasis in a patient with Crohn's disease.
Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
[No Abstract] [Full Text] [Related]
36. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy.
Ettler J; Wetter DA; Pittelkow MR
Clin Exp Dermatol; 2012 Aug; 37(6):639-41. PubMed ID: 22300412
[TBL] [Abstract][Full Text] [Related]
37. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
[TBL] [Abstract][Full Text] [Related]
38. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
39. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
Sànchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Villaverde R
Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S128. PubMed ID: 17067448
[No Abstract] [Full Text] [Related]
40. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
Le Bidre E; Chaby G; Martin L; Perrussel M; Sassolas B; Sigal ML; Kaassis C; Lespessailles E; Nseir A; Estève E
Ann Dermatol Venereol; 2011; 138(4):285-93. PubMed ID: 21497255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
